N-[4-(dimethylamino)phenyl]-2-phenylquinoline-4-carboxamide | 300852-09-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[4-(dimethylamino)phenyl]-2-phenylquinoline-4-carboxamide
• CAS: 300852-09-9
• 化学式: C₂₄H₂₁N₃O
• 分子量: 367.45
• InChiKey: XVALPIOZOKELQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[4-(dimethylamino)phenyl]-2-phenylquinoline-4-carboxamide 在 碘 、 calcium oxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 4.0h， 以55%的产率得到N-(4-(methylamino)phenyl)-2-phenylquinoline-4-carboxamide
  参考文献：
  名称：

  Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates

  摘要：

  药物及药物候选物代谢物的鉴定和定量通常使用液相色谱-质谱联用技术 (LC-MS) 进行。最佳实践是生成以代谢物与内标的标准曲线。然而，为了避免代谢物合成的困难，有时会使用底物来准备标准曲线，假设底物和代谢物的信号是等效的。我们使用一系列非常相似的化合物，这些化合物经历共同的代谢反应，测试了这一假设所带来的误差，采用了传统流动电喷雾电离 LC-MS 和低流量捕获喷雾电离 (CSI) LC-MS 方法。文中展示了四种不同转化类型（O-去甲基化、N-去甲基化、芳香族羟基化和苄基羟基化）的标准曲线差异。结果表明，在20种底物-代谢物组合中的18种情况下，两种方法中底物和代谢物的信号在统计上是显著不同的。标准曲线的斜率比率最高可变化4倍，但CSI方法的变化略小。

  DOI：

  10.1124/dmd.111.040865
• 作为产物：
  描述：

  2-苯基-4-喹啉羧酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-[4-(dimethylamino)phenyl]-2-phenylquinoline-4-carboxamide
  参考文献：
  名称：

  Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates

  摘要：

  药物及药物候选物代谢物的鉴定和定量通常使用液相色谱-质谱联用技术 (LC-MS) 进行。最佳实践是生成以代谢物与内标的标准曲线。然而，为了避免代谢物合成的困难，有时会使用底物来准备标准曲线，假设底物和代谢物的信号是等效的。我们使用一系列非常相似的化合物，这些化合物经历共同的代谢反应，测试了这一假设所带来的误差，采用了传统流动电喷雾电离 LC-MS 和低流量捕获喷雾电离 (CSI) LC-MS 方法。文中展示了四种不同转化类型（O-去甲基化、N-去甲基化、芳香族羟基化和苄基羟基化）的标准曲线差异。结果表明，在20种底物-代谢物组合中的18种情况下，两种方法中底物和代谢物的信号在统计上是显著不同的。标准曲线的斜率比率最高可变化4倍，但CSI方法的变化略小。

  DOI：

  10.1124/dmd.111.040865

文献信息

• SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20210244721A1

  公开（公告）日：2021-08-12

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and/or androgen receptor expression.

  这项发明属于药物化学领域。具体而言，该发明涉及一类新型的小分子，其具有喹啉（或类似）结构，可作为雄激素受体活性拮抗剂，并且可用作治疗癌症（例如去势抵抗性前列腺癌）和其他与雄激素受体活性和/或雄激素受体表达有关的疾病的治疗药物。
• Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68)
  作者：Rami Musharrafieh、Jiantao Zhang、Peter Tuohy、Naoya Kitamura、Shreya Sai Bellampalli、Yanmei Hu、Rajesh Khanna、Jun Wang

  DOI：10.1021/acs.jmedchem.9b00115

  日期：2019.4.25

  Enterovirus D68 (EV-D68) is an atypical nonpolio enterovirus that mainly infects the respiratory system of humans, leading to moderate-to-severe respiratory diseases. In rare cases, EV-D68 can spread to the central nervous system and cause paralysis in infected patients, especially young children and immunocompromised individuals. There is currently no approved vaccine or antiviral available for the prevention and treatment of EV-D68. In this study, we aimed to improve the antiviral potency and selectivity of a previously reported EV-D68 inhibitor, dibucaine, through structure activity relationship studies. In total, 60 compounds were synthesized and tested against EV-D68 using the viral cytopathic effect assay. Three compounds 10a, 12a, and 12c were identified to have significantly improved potency (EC50 < 1 mu M) and a high selectivity index (>180) compared with dibucaine against five different strains of EV-D68 viruses. These compounds also showed potent antiviral activity in neuronal cells, such as A172 and SH-SY5Y cells, suggesting they might be further developed for the treatment of both respiratory infection as well as neuronal infection.
• Comparative Study of the Affinity and Metabolism of Type I and Type II Binding Quinoline Carboxamide Analogues by Cytochrome P450 3A4
  作者：Upendra P. Dahal、Carolyn Joswig-Jones、Jeffrey P. Jones

  DOI：10.1021/jm201207h

  日期：2012.1.12

  Compounds that coordinate to the heme-iron of cytochrome P450 (CYP) enzymes are assumed to increase metabolic stability. However, recently we observed that the type II binding quinoline carboxamide (QCA) compounds were metabolically less stable. To test if the higher intrinsic clearance of type II binding compounds relative to type I binding compounds is general for other metabolic transformations, we synthesized a library of QCA compounds that could undergo N-dealkylation, O-dealkylation, benzylic hydroxylation, and aromatic hydroxylation. The results demonstrated that type II binding QCA analogues were metabolically less stable (2- to 12-fold) at subsaturating concentration compared to type I binding counterparts for all the transformations. When the rates of different metabolic transformations between type I and type II binding compounds were compared, they were found to be in the order of N-demethylation > benzylic hydroxylation > O-demethylation > aromatic hydroxylation. Finally, for the QCA analogues with aza-heteroaromatic rings, we did not detect metabolism in aza-aromatic rings (pyridine, pyrazine, pyrimidine), indicating that electronegativity of the nitrogen can change regioselectivity in CYP metabolism.